3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
6
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Micrometastasis
1
Lymphatic Metastasis
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
5
Cyclophosphamide
2
trastuzumab deruxtecan
1
tislelizumab
1
spartalizumab
1
nanocis
1
fludarabine
1
enzalutamide
1
entinostat
1
cemiplimab
1
atezolizumab
1
abiraterone
1
Thalidomide
1
Technetium-99
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Mesna
1
Ipilimumab
1
Interleukin-2
1
Infracyanine green
1
Indocyanine Green
1
Indinavir
1
Immunotherapy
1
Immunohistochemistry
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
Indocyanine Green
×
Dermatologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled